Tavanta Therapeutics names new CMO and appoints VP of clinical development
13 July 2021 -

Tavanta Therapeutics, a specialty pharmaceutical company, announced on Monday that it has named Andreas Maetzel, MD, PhD as its new chief medical officer and promoted Elizabeth Manning Duus, PhD as vice president of clinical development.

Dr Maetzel has more than two decades of experience with biotechnology products and rare disease interventions. He has served as senior vice president, medical and held senior global medical affairs positions with BioCryst Pharmaceuticals and Cornerstone Biopharma.

Dr Duus has 15 years of clinical research experience in the biopharmaceutical industry covering early and late development across multiple therapeutic areas.